share_log

Stephens & Co. Initiates Coverage On Cytek Biosciences With Overweight Rating, Announces Price Target of $9

Stephens & Co. Initiates Coverage On Cytek Biosciences With Overweight Rating, Announces Price Target of $9

Stephens & Co.以增持評級啓動對Cytek Biosciences的報道,宣佈目標股價爲9美元
Benzinga ·  2023/12/14 05:46

Stephens & Co. analyst Mason Carrico initiates coverage on Cytek Biosciences (NASDAQ:CTKB) with a Overweight rating and announces Price Target of $9.

斯蒂芬斯公司分析師梅森·卡里科以增持評級啓動了對Cytek Biosciences(納斯達克股票代碼:CTKB)的報道,並宣佈目標股價爲9美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論